Nautilus Biotechnology, Inc. (NAUT) AI Dilution Summary

Estimated cash was $84,031,000 as of 2026-06-30, the last reported balance-sheet date, against estimated monthly burn of $4,575,333. The funding channel in place is an active at-the-market program with TD Securities (USA) LLC (TD Cowen), authorised to $125,000,000. Dilution here is driven primarily by S-3 shelf registration 333-298884.